Latest News

Eisenhower Fellowships has launched its 2022 USA Justice Program with an inaugural cohort of 11 mid-career US professionals from a variety of fields, including psychiatry, to address issues in inequality.

One psychiatrist considers the advantages of virtual psychiatric treatment for both patients and clinicians.

Real true, posttraumatic stress disorder [PTSD] is going to have an impact, certainly on the next generation and maybe generations after that," said Rachel Yehuda, PhD.

In an overwhelming approval the FDA approved the use of Esketamine nasal spary, known as <em>SPRAVATO™, </em>for the treatment of drug resistant major depressive disorder. A major step for those that support the use of ketamine in the treatment of depression.

Rare genetic variants can have an effect on the N-methyl-D-aspartate receptor that carries brain signals between brain cells in response to glutamate. A recent study on the receptor revealed these genetic variants might have an implication on the development of Schizophrenia.

Electroconvulsive Therapy Devices have varying uses due to their complicated benefits and risks. The FDA recently recgonized this and now ECT devices have been reclassfied.

In its third Phase III study, SPN-812 met its primary endpoint with positive results. Marking a major step for Supernus Pharmaceuticals novel ADHD treatment.<br /> <br />

Researchers from the Picower Institute for Learning and Memory at MIT have found a link between SYNE1 Gene Mutations and the expression of CPG2 protein. Which is linked to having bipolar disorder. <br />

Axsome Therapeutics recently announced that its novel drug AXS-05 met its primary endpoints in a Phase 2 trial, that could see the drug have a major positive impact on the major depressive disorder population. <br />